CN111050762A - 减轻肺部炎症的方法 - Google Patents

减轻肺部炎症的方法 Download PDF

Info

Publication number
CN111050762A
CN111050762A CN201880041015.9A CN201880041015A CN111050762A CN 111050762 A CN111050762 A CN 111050762A CN 201880041015 A CN201880041015 A CN 201880041015A CN 111050762 A CN111050762 A CN 111050762A
Authority
CN
China
Prior art keywords
dose
chelating agent
formulation
inflammation
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880041015.9A
Other languages
English (en)
Chinese (zh)
Inventor
B.克莱门茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rsprion Pharmaceuticals Pte Ltd
Original Assignee
Rsprion Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902365A external-priority patent/AU2017902365A0/en
Application filed by Rsprion Pharmaceuticals Pte Ltd filed Critical Rsprion Pharmaceuticals Pte Ltd
Publication of CN111050762A publication Critical patent/CN111050762A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880041015.9A 2017-06-20 2018-06-20 减轻肺部炎症的方法 Pending CN111050762A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902365 2017-06-20
AU2017902365A AU2017902365A0 (en) 2017-06-20 Method For Reducing Lung Inflammation
PCT/AU2018/050609 WO2018232452A1 (en) 2017-06-20 2018-06-20 METHOD FOR REDUCING PULMONARY INFLAMMATION

Publications (1)

Publication Number Publication Date
CN111050762A true CN111050762A (zh) 2020-04-21

Family

ID=64735378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041015.9A Pending CN111050762A (zh) 2017-06-20 2018-06-20 减轻肺部炎症的方法

Country Status (8)

Country Link
US (2) US11491126B2 (https=)
EP (1) EP3641749A4 (https=)
JP (3) JP7729713B2 (https=)
CN (1) CN111050762A (https=)
AU (2) AU2018286649B2 (https=)
BR (1) BR112019027257A2 (https=)
CA (1) CA3067857A1 (https=)
WO (1) WO2018232452A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059380A (zh) * 2021-10-29 2023-05-05 原创生医股份有限公司 用于上呼吸道给药的组成物及其给药方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection
WO2017096013A1 (en) * 2015-12-01 2017-06-08 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection
WO2017096013A1 (en) * 2015-12-01 2017-06-08 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K.M.HILLMAN等: "AEROSOL EDTA TO ELIMINATE RESPIRATORY-TRACT PSEUDOMONAS", 《THE LANCET》 *
MARAL AALIDENG: "Iron chelation as novel treatment for lung inflammation in cystic fibrosis", 《MEDICAL HYPOTHESES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059380A (zh) * 2021-10-29 2023-05-05 原创生医股份有限公司 用于上呼吸道给药的组成物及其给药方法

Also Published As

Publication number Publication date
AU2023270302A1 (en) 2023-12-14
EP3641749A4 (en) 2021-03-17
AU2023270302B2 (en) 2025-10-23
AU2018286649B2 (en) 2023-11-09
US20200163920A1 (en) 2020-05-28
CA3067857A1 (en) 2018-12-27
JP2025098035A (ja) 2025-07-01
JP2020524173A (ja) 2020-08-13
BR112019027257A2 (pt) 2020-07-14
JP2023071952A (ja) 2023-05-23
JP7729713B2 (ja) 2025-08-26
WO2018232452A1 (en) 2018-12-27
JP7848150B2 (ja) 2026-04-20
AU2018286649A1 (en) 2019-12-05
US11491126B2 (en) 2022-11-08
EP3641749A1 (en) 2020-04-29
US20230045633A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US20120058198A1 (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
Sermet-Gaudelus et al. Nebulized antibiotics in cystic fibrosis
KR101803121B1 (ko) 포스포디에스테라제 억제제를 포함하는 약학적 제제
CN120285204A (zh) 用于治疗肺的组合物和方法
JP7642033B2 (ja) 肺感染症を低減させる方法
JP4745340B2 (ja) 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
JP2014523909A (ja) 人工呼吸器関連肺炎（ｖａｐ）及び人工呼吸器関連気管（ｖａｔ）気管支炎の治療のためのアミカシンとホスホマイシンの組み合わせの製剤並びに方法及びシステム
JP2025098035A (ja) 肺炎症を低減させる方法
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
TW201138785A (en) Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
Hasan et al. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
WO2021205074A1 (en) Inhalable formulation
Fila et al. 73 Influence of treatment with sildenafil on lung function and exercise tolerance in cystic fibrosis adults
Bragonzi et al. WS7. 1 Pre-clinical evaluation of novel antibiotic POL7001 against Pseudomonas aeruginosa in lung infection models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination